Image: Moderator: Roger Longman, Real Endpoints Faculty: Chris Wiwi, PhD, SVP, Technical Operations, Carlton Sedberry, CEO, Immunobridge, Michael Sherman, MD, former CMO, Point32/Harvard Pilgrim, Becky Cap, MBA, SVP, Biotherapies, Vitalant, Merlene Varughese, Senior Director, Value, Access & Pricing Strategy, CAR-T at Johnson & Johnson
This year, EMOL Health leaders attended the 15th Annual Association for Value-Based Cancer Care (AVBCC) Summit, held at the New York Athletic Club in New York City from October 22 to 24, 2025. The summit brought together stakeholders from across the oncology care continuum to discuss the latest trends and challenges in value-based cancer care.
Carlton Sedberry, DPh, Immunobridge CEO, participated in the newly formed Cell Therapy Commercialization Symposium, lending his expertise to the Aligning the Misaligned in Cell Therapy, along with other leaders in the CAR-T space. The panel focused on the commercial and medical challenges with bringing cell therapy into community practices. To address these challenges a high-powered selection of executives representing very different parts of this ecosystem discussed the landscape.